RT Journal Article
SR Electronic
T1 Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1393
OP 1402
DO 10.1183/09031936.00105314
VO 45
IS 5
A1 David S. Wilkes
A1 Terrence Chew
A1 Kevin R. Flaherty
A1 Sarah Frye
A1 Kevin F. Gibson
A1 Naftali Kaminski
A1 Michael J. Klemsz
A1 Wade Lange
A1 Imre Noth
A1 Katia Rothhaar
YR 2015
UL http://erj.ersjournals.com/content/45/5/1393.abstract
AB Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. IPF appears to be heterogeneous in pathobiology with ∼40% of IPF patients found to have elevated levels of circulating antibodies to the autoantigen type V collagen (col(V)). Following a targeted, precision medicine approach, we conducted a phase 1 study to test the safety and explore potential efficacy of IW001, a col(V) oral immunotherapeutic developed to treat antibody-positive IPF patients. We divided 30 antibody-positive IPF patients into three cohorts for daily dosing over a 24-week period. All patients completed treatment without serious adverse events, acute exacerbations or IPF-related hospitalisations. A decline in lung function occurred in the lowest-dose cohort that was comparable to that reported in placebo arms of published IPF trials. In contrast, the highest-dose cohort showed a trend toward stabilisation of forced vital capacity and matrix metalloproteinase 7, and a reduction in binding of C1q to anti-col(V) antibodies. IW001 may modulate the immune response to col(V) and may represent a new therapeutic for col(V)- reactive IPF patients. IW001 is safe, and improves biomarkers and lung function in IPF patients with type V collagen antibodies http://ow.ly/LirbO